PRPO Split History

Precipio (PRPO) has 1 split in our PRPO split history database. The split for PRPO took place on April 29, 2019. This was a 1 for 15 reverse split, meaning for each 15 shares of PRPO owned pre-split, the shareholder now owned 1 share. For example, a 1000 share position pre-split, became a 66.6666666666667 share position following the split.

When a company such as Precipio conducts a reverse share split, it is usually because shares have fallen to a lower per-share pricepoint than the company would like. This can be important because, for example, certain types of mutual funds might have a limit governing which stocks they may buy, based upon per-share price. The $5 and $10 pricepoints tend to be important in this regard. Stock exchanges also tend to look at per-share price, setting a lower limit for listing eligibility. So when a company does a reverse split, it is looking mathematically at the market capitalization before and after the reverse split takes place, and concluding that if the market capitilization remains stable, the reduced share count should result in a higher price per share.

Looking at the PRPO split history from start to finish, an original position size of 1000 shares would have turned into 66.6666666666667 today. Below, we examine the compound annual growth rate — CAGR for short — of an investment into Precipio shares, starting with a $10,000 purchase of PRPO, presented on a split-history-adjusted basis factoring in the complete PRPO split history.

Growth of $10,000.00 Without Dividends Reinvested
Start date:	07/07/2017
End date:	09/21/2023
Start price/share:	$166.46
End price/share:	$0.27
Dividends collected/share:	$0.00
Total return:	-99.84%
Average Annual Total Return:	-64.56%
Starting investment:	$10,000.00
Ending investment:	$15.92
Years:	6.21

About Precipio

Precipio is a healthcare biotechnology company focused on cancer diagnostics. Co. develops and sells diagnostic products, reagents and services. The first panel developed using HemeScreen technology was Co.'s Myeloproliferative Neoplasms panel. Co. has since added Acute Myeloid Leukemia, Chronic Lymphocytic Leukemia, Cytopenia, and BCR-ABL panels, evolving HemeScreen into a suite of genetic diagnostic panels. Co.'s IV-Cell is a proprietary cell culture media that addresses the problem of diagnostic mistakes through the process of selective culturing. IV-Cell is a media that enables simultaneous culturing of four hematopoietic cell lineages. According to our PRPO split history records, Precipio has had 1 split.